Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company focused on identifying, developing, and delivering therapies to patients living with rare kidney and metabolic diseases. The company maintains its headquarters in San Diego, California, and operates with a strategic vision to become a leading innovator in the rare disease treatment space.

The company's commercial portfolio centers on FILSPARI (sparsentan), which received full FDA approval in September 2024 for slowing kidney function decline in adults with primary Immunoglobulin A nephropathy (IgAN). FILSPARI is the only oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury by blocking endothelin-1 and angiotensin II pathways. The company also markets Thiola and Thiola EC (tiopronin) for treating cystinuria, a rare genetic cystine transport disorder. In August 2023, Travere divested its bile acid product portfolio, including Chenodal and Cholbam, to Mirum Pharmaceuticals, with potential milestone payments tied to future sales performance.

The clinical pipeline includes sparsentan for focal segmental glomerulosclerosis (FSGS), with a supplemental new drug application under FDA review with a target action date of April 13, 2026. The company is also advancing pegtibatinase, a novel enzyme replacement therapy for classical homocystinuria (HCU), currently in pivotal Phase 3 HARMONY Study development following a voluntary enrollment pause to optimize manufacturing processes. Enrollment activities restarted in the first quarter of 2026.

Travere has established strategic partnerships to expand its global reach. The company licensed sparsentan rights to CSL Vifor for European markets and to Chugai Pharmaceutical for Japan, South Korea, and Taiwan. In April 2025, the European Commission converted FILSPARI's conditional marketing authorization to standard approval, and the company received a $17.5 million regulatory milestone payment.

The company's business model emphasizes reinvesting revenues from commercialized products into research and development efforts. Travere operates with an accelerated filer status and maintains a disciplined approach to in-licensing and acquisition opportunities, focusing on therapeutic candidates addressing severe unmet medical needs in rare disease populations with identifiable orphan drug designations.